Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, Pinto Correia A, Natalie CR, Rodriguez Capriles C, Pierce E, Reifeis S, Gontijo Lima R, Armengol Tubau C, Laquer V, Weidinger S. Paller AS, et al. Among authors: pierce e. Dermatol Ther (Heidelb). 2023 Jul;13(7):1517-1534. doi: 10.1007/s13555-023-00942-y. Epub 2023 Jun 15. Dermatol Ther (Heidelb). 2023. PMID: 37318750 Free PMC article.
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, Silverberg JI, Rueda MJ, DeLozier AM, Pierce E, Yang FE, Sun L, Ball S, Tauber M, Paul C. Wollenberg A, et al. Among authors: pierce e. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1543-1552. doi: 10.1111/jdv.17278. Epub 2021 Jun 5. J Eur Acad Dermatol Venereol. 2021. PMID: 33834521 Free PMC article. Clinical Trial.
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
Yosipovitch G, Papp K, Forman S, Han G, Waibel J, Rueda MJ, Sun L, Chen YF, Goldblum O, Pierce E, Silverberg JI. Yosipovitch G, et al. Among authors: pierce e. Br J Dermatol. 2022 Jun;186(6):1047-1049. doi: 10.1111/bjd.21015. Epub 2022 Apr 21. Br J Dermatol. 2022. PMID: 35041213 Free PMC article. Clinical Trial.
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
Silverberg JI, Simpson EL, Thyssen JP, Werfel T, Cardillo TE, Colvin S, Pierce E, Chen YF, Chen S, Eichenfield L. Silverberg JI, et al. Among authors: pierce e. J Eur Acad Dermatol Venereol. 2023 May;37(5):1036-1045. doi: 10.1111/jdv.18816. Epub 2023 Jan 20. J Eur Acad Dermatol Venereol. 2023. PMID: 36514996 Clinical Trial.
539 results